When will the BECONASE AQ patents expire, and when will generic BECONASE AQ be available?

Sponsor	Phase
West Penn Allegheny Health System	Phase 4
Glaucoma Research Society of Canada	N/A
University Health Network, Toronto	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BECONASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019389-001	Jul 27, 1987		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Beconase AQ is a legacy intranasal corticosteroid containing beclomethasone dipropionate. Its commercial position has weakened because core composition and delivery patents have expired, generic and OTC intranasal steroid competition has expanded, and newer products offer stronger brand recognition or differentiated delivery. Public filings do not disclose standalone Beconase AQ revenue. The product’s financial trajectory is therefore best characterized as mature-to-declining, with limited strategic value except as a low-cost generic or portfolio-completion product.

What is Beconase AQ and how does it work?

Beconase AQ is an aqueous nasal spray containing beclomethasone dipropionate, a synthetic glucocorticoid used to treat allergic rhinitis. The product reduces nasal inflammation, congestion, sneezing, and rhinorrhea through local corticosteroid activity in the nasal mucosa (U.S. Food and Drug Administration [FDA], 2019).

The product is distinct from QNASL, an aerosolized nasal formulation of beclomethasone dipropionate. Beconase AQ uses an aqueous suspension, while QNASL uses a hydrofluoroalkane propellant-based delivery system. The products therefore have different formulations, devices, and regulatory histories.

Attribute	Beconase AQ
Active ingredient	Beclomethasone dipropionate
Dosage form	Aqueous nasal spray
Strength	42 mcg per spray
Route	Intranasal
Primary indication	Seasonal and perennial allergic rhinitis
Original sponsor	GlaxoSmithKline and predecessor companies
FDA regulatory pathway	New Drug Application
FDA application	NDA 020505
Market category	Intranasal corticosteroid
Current commercial profile	Legacy product with limited brand momentum
Biosimilar relevance	None; this is a small-molecule drug

The product’s clinical value remains intact, but the commercial value of its branded formulation has eroded.

What is the FDA regulatory status of Beconase AQ?

Beconase AQ was approved through the FDA’s NDA pathway and is identified in FDA product databases under NDA 020505. Its approved use is treatment of nasal symptoms associated with allergic rhinitis (FDA, n.d.-a).

The regulatory position has three important commercial implications:

Beconase AQ is a small-molecule nasal product, not a biologic.
Generic applicants can rely on the Abbreviated New Drug Application pathway if they demonstrate pharmaceutical equivalence and bioequivalence.
The product does not receive biosimilar protection or biologic exclusivity.

The FDA label identifies the principal risks associated with intranasal corticosteroid use, including epistaxis, nasal ulceration, Candida infections, impaired wound healing, glaucoma, cataracts, and potential systemic corticosteroid effects. These risks are generally class-wide and do not provide substantial differentiation for Beconase AQ (FDA, 2019).

Was Beconase AQ withdrawn for safety reasons?

There is no established indication that Beconase AQ lost commercial status because of a safety withdrawal. Its market deterioration is more consistent with lifecycle aging, generic substitution, competitive pressure, and portfolio rationalization.

That distinction matters. A commercial discontinuation or limited availability status does not establish that the product is unsafe or that the FDA withdrew approval for safety reasons. FDA application databases distinguish regulatory approval from current marketing activity (FDA, n.d.-a).

When does Beconase AQ lose exclusivity?

Beconase AQ’s principal product-level exclusivity has expired. The drug was introduced decades ago, and the composition-of-matter and early formulation protection associated with beclomethasone dipropionate nasal therapy are no longer meaningful barriers to generic entry.

Protection category	Beconase AQ position
Original compound patent	Expired
Original nasal formulation protection	Expired or commercially ineffective
FDA new chemical entity exclusivity	Expired
Pediatric exclusivity	Expired, if previously granted
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Current practical protection	Brand recognition, regulatory know-how, and supply economics

A precise patent-expiration analysis must distinguish Beconase AQ from QNASL. Patents covering QNASL’s aerosol formulation, device, or manufacturing process do not automatically protect Beconase AQ’s aqueous nasal spray.

What patents protect Beconase AQ?

The commercially relevant patent estate for Beconase AQ is effectively exhausted. The original drug and conventional aqueous nasal spray technology are old enough that any foundational patents would have expired under the 20-year patent term applicable to modern U.S. patent practice.

The remaining defensible positions, if any, would be narrow and could include:

Device or actuator geometry.
Specific suspension characteristics.
Preservative systems.
Manufacturing controls.
Packaging configurations.
Labeling claims tied to a particular patient population.

These categories would not normally create a durable franchise. A generic manufacturer could design around a narrow device or process claim while maintaining the same active ingredient and therapeutic purpose.

Does Beconase AQ have active Orange Book patents?

Beconase AQ does not have a commercially meaningful active Orange Book patent position. The Orange Book is the relevant FDA source for approved products, therapeutic equivalence codes, and listed patents or exclusivity information (FDA, n.d.-b).

The lack of meaningful active patent protection increases the probability of generic substitution. It also limits the value of Paragraph IV litigation because the brand would need an enforceable listed patent to obtain the standard 30-month stay following a qualifying ANDA challenge.

Have generic manufacturers challenged Beconase AQ?

The principal competitive threat is generic substitution rather than an active, high-value Paragraph IV campaign.

An ANDA applicant can seek approval for a therapeutically equivalent beclomethasone dipropionate nasal spray by referencing the relevant branded NDA. If an active listed patent is absent, the applicant would generally file a Paragraph III or certification pathway rather than mount a Paragraph IV patent challenge. A Paragraph IV certification is relevant only when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

Generic-entry issue	Beconase AQ exposure
Paragraph IV risk	Low as a litigation event because foundational patents are expired
ANDA filing risk	High where a reference product remains eligible for generic development
Patent-based launch block	Limited
Formulation development risk	Moderate, because nasal suspension performance must be matched
Device-development risk	Moderate but manageable
Price erosion	High
Brand retention	Low without commercial differentiation

The principal barrier is technical equivalence, not patent enforcement. Nasal products can require detailed comparative performance work involving spray pattern, plume geometry, droplet or particle-size distribution, priming, re-priming, delivered dose, and suspension uniformity.

What formulations are protected by Beconase AQ?

Beconase AQ’s key formulation characteristic is an aqueous suspension of beclomethasone dipropionate delivered through a metered nasal spray. The formulation must maintain dose uniformity despite the low aqueous solubility of the active ingredient.

The formulation and device impose several development requirements:

Consistent suspension of active particles.
Accurate metering across the labeled number of sprays.
Reliable spray performance after storage.
Appropriate preservative performance.
Acceptable nasal tolerability.
Device compatibility with the formulation.
Stability under normal and accelerated conditions.

These requirements can slow generic development, but they do not constitute durable exclusivity. Once a generic applicant establishes pharmaceutical equivalence and obtains FDA approval, the brand’s ability to sustain premium pricing is limited.

QNASL is a separate formulation strategy. Its aerosol delivery system may have supported more recent patent claims, but those claims should not be treated as protection for Beconase AQ.

How does Beconase AQ compare with competing intranasal steroids?

Beconase AQ competes in a crowded therapeutic class that includes fluticasone propionate, fluticasone furoate, triamcinolone acetonide, budesonide, mometasone furoate, and newer beclomethasone products.

Product or ingredient	Commercial position	Key competitive factor
Beconase AQ	Legacy branded or limited-availability product	Low differentiation and old brand
Flonase, fluticasone propionate	Major OTC and generic competitor	Strong consumer recognition and broad distribution
Flonase Sensimist, fluticasone furoate	Premium OTC positioning	Device and sensory differentiation
Nasacort, triamcinolone acetonide	OTC and generic competitor	Price and broad retail presence
Rhinocort, budesonide	OTC and generic competitor	Consumer familiarity and allergy positioning
Nasonex, mometasone furoate	Branded and generic competitor	Established efficacy and low-systemic-exposure messaging
QNASL, beclomethasone dipropionate	Differentiated prescription product	Aerosol formulation and device

Fluticasone-based products have exerted the greatest commercial pressure because they combine strong clinical recognition with extensive retail distribution. OTC availability has shifted purchasing power toward retailers, pharmacy benefit managers, and consumer brands rather than prescription-product sponsors.

Beconase AQ also lacks a clear delivery or sensory advantage over modern competitors. Intranasal corticosteroids are often judged on congestion relief, taste, drip, spray feel, ease of use, and price. A legacy aqueous suspension has limited room to command a premium unless the brand has strong distribution or a differentiated label.

What is the market size for intranasal corticosteroids?

Intranasal corticosteroids form one of the largest and most mature segments of the allergic-rhinitis market. Demand is recurring and seasonal, but the category has experienced significant commoditization.

Market dynamics include:

High prevalence of allergic rhinitis.
Seasonal volume peaks in spring and early summer.
Extensive OTC substitution.
Low switching costs among corticosteroid sprays.
Generic price competition.
Retail promotion and shelf placement as major purchase drivers.
Limited clinical differentiation among established products.

The market’s growth is therefore driven more by population, diagnosis, allergy-season severity, and OTC consumption than by premium pricing. Beconase AQ is exposed to the least favorable part of this structure: an older product with limited patent protection and no obvious consumer-facing advantage.

What is the financial trajectory of Beconase AQ?

Public company filings do not report standalone revenue, gross margin, operating income, or unit volume for Beconase AQ. GlaxoSmithKline historically reported broader pharmaceutical and respiratory portfolios, not individual mature products such as Beconase AQ.

The product’s likely financial trajectory is:

Period	Financial profile
Initial launch and growth	Prescription revenue supported by brand promotion and limited competition
Maturity	Stable but slowing demand as newer nasal steroids gained share
Generic-entry period	Volume retention with sharp price and margin pressure
OTC-heavy market period	Reduced strategic value and weaker brand leverage
Current legacy phase	Limited revenue contribution, possible discontinuation or restricted distribution

Revenue exposure is likely immaterial to the consolidated financial statements of a major multinational manufacturer. The product may still generate small licensing, distribution, or residual supply revenue, but it is unlikely to influence group-level earnings.

The more relevant financial question is whether the product imposes costs:

Manufacturing and quality-system maintenance.
Pharmacovigilance.
Regulatory filing maintenance.
Supply-chain complexity.
Inventory write-offs.
Contract manufacturing commitments.
Customer-service and distribution expenses.

For a mature product with weak pricing power, discontinuation can improve economics even when the product still produces positive gross margin. Portfolio managers typically evaluate the product on contribution margin, compliance burden, and opportunity cost rather than revenue alone.

Which companies are challenging Beconase AQ commercially?

Competition comes primarily from generic manufacturers and large OTC allergy brands rather than from patent litigants.

Relevant competitive groups include:

Generic manufacturers selling beclomethasone or competing intranasal corticosteroids.
Haleon, through Flonase-related OTC products following the separation of its consumer-health business from GSK.
Kenvue, through allergy and nasal-health brands associated with the former Johnson & Johnson consumer-health portfolio.
Sanofi and other consumer-health companies with allergy products.
Retail pharmacy and private-label manufacturers.
Specialty and generic respiratory-product companies.

The competitive landscape favors companies with scale in procurement, retail distribution, OTC advertising, and pharmacy contracting. Beconase AQ’s historical sponsor has less ability to justify dedicated investment in a mature product than it had during the prescription-growth period.

What manufacturing and intellectual-property barriers remain?

The manufacturing barrier is moderate. Beclomethasone dipropionate is an established active ingredient, and aqueous nasal spray manufacturing is a mature technology. The more difficult elements are product-specific process control and device performance.

Potential barriers include:

Suspension uniformity across the bottle life.
Metering consistency after storage and repeated use.
Spray-pattern matching.
Microbiological control.
Container-closure integrity.
Stability of the formulation and device combination.
FDA comparative-performance expectations for nasal products.

These barriers may delay a generic launch, but they are unlikely to support long-term premium pricing. The product does not have a biologic manufacturing barrier, complex peptide structure, or highly specialized delivery technology.

What generic launch scenarios exist for Beconase AQ?

Three scenarios are commercially plausible.

Scenario 1: Generic substitution with rapid price erosion

This is the most likely outcome when a therapeutically equivalent generic is available and the branded product has limited retail support. Pharmacy substitution reduces branded volume, while payers impose lower reimbursement.

Scenario 2: Limited brand persistence

Beconase AQ may retain a small user base because of physician familiarity, patient tolerance, or formulary placement. The brand could continue at a reduced price or through a niche distributor.

Scenario 3: Commercial discontinuation

If manufacturing, compliance, and distribution costs exceed contribution margin, the sponsor may stop marketing the product. The FDA approval can remain in the database even after commercial supply ends.

The probability of a premium relaunch is low unless a company introduces a meaningful device, dosing, or consumer-experience improvement. A simple rebranding of the existing aqueous spray would face strong substitution pressure.

What litigation and settlement agreements affect Beconase AQ?

No major current patent litigation or settlement agreement is central to Beconase AQ’s commercial outlook. The product’s legal risk is primarily ordinary generic substitution and regulatory compliance.

The absence of active litigation reflects the age of the product and the lack of a valuable blocking patent estate. Any historical disputes would have limited relevance unless they affected an active product, an ANDA approval, or a continuing supply arrangement.

How strong is the Beconase AQ patent estate?

The patent estate is weak from an investment or licensing perspective.

Patent-estate factor	Assessment
Composition-of-matter protection	Exhausted
Core formulation protection	Exhausted or ineffective
Device claims	Potentially narrow and design-aroundable
Manufacturing claims	Limited commercial leverage
Orange Book exclusivity	No meaningful current protection
Litigation leverage	Low
Generic-entry resistance	Low to moderate for technical reasons, low for IP reasons
Licensing value	Low unless bundled with broader respiratory assets

The product’s residual value is operational rather than intellectual-property based. A buyer would value manufacturing capability, regulatory history, customer relationships, or a broader nasal-products portfolio more than Beconase AQ patents.

What is the outlook for Beconase AQ revenue?

Standalone revenue is not publicly available, so no defensible product-specific forecast can be stated. The direction, however, is clear:

Prescription demand has matured.
Generic and OTC alternatives have reduced pricing power.
Brand investment has likely declined.
Product-level revenue is unlikely to be material to a multinational sponsor.
Any remaining value is concentrated in residual demand, supply agreements, or portfolio bundling.

The product should be treated as a declining legacy asset rather than a growth pharmaceutical. Its financial performance is more likely to track market contraction and distribution decisions than clinical adoption.

Key Takeaways

Beconase AQ is a legacy aqueous nasal spray containing beclomethasone dipropionate.
Its foundational patent and regulatory exclusivity protections have expired.
The product has no biosimilar exposure because it is a small-molecule drug.
Generic substitution and OTC intranasal corticosteroids are the primary competitive threats.
Formulation and nasal-device requirements create moderate development barriers but do not create durable exclusivity.
No material current Paragraph IV litigation or settlement structure drives the product’s outlook.
GSK and predecessor companies did not publicly report standalone Beconase AQ revenue.
The product’s financial trajectory is mature-to-declining, with limited strategic value unless bundled with broader nasal or respiratory assets.
Fluticasone, triamcinolone, budesonide, and mometasone products have stronger current commercial positioning in the intranasal corticosteroid market.
The most likely commercial outcomes are low-price generic substitution, limited brand persistence, or discontinuation.

FAQs About Beconase AQ Market and Financial Position

Is Beconase AQ still sold in the United States?

Beconase AQ is a legacy U.S. product with limited commercial momentum. FDA application records can continue to identify the NDA even when commercial availability is restricted or discontinued.

Is Beconase AQ the same as QNASL?

No. Both contain beclomethasone dipropionate, but Beconase AQ is an aqueous nasal spray and QNASL is an aerosolized nasal formulation with a different delivery system.

Can a generic manufacturer launch Beconase AQ without patent litigation?

Yes. Because core product protection has expired, a generic applicant can pursue an ANDA pathway without relying on a high-value Paragraph IV dispute, subject to FDA approval requirements.

Does Beconase AQ have biosimilar competition?

No. Biosimilar rules apply to biological products. Beconase AQ contains a conventional synthetic small-molecule corticosteroid and is subject to generic-drug rules.

Is Beconase AQ commercially attractive for licensing?

Its standalone licensing value is low. A transaction could make economic sense only if Beconase AQ is included in a broader portfolio involving nasal manufacturing capacity, regional distribution rights, or multiple respiratory products.

References

GlaxoSmithKline. (2019). Beconase AQ: Beclomethasone dipropionate nasal spray prescribing information. U.S. Food and Drug Administration.
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: Beconase AQ, NDA 020505. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application abbreviated approval pathway. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
U.S. Food and Drug Administration. (n.d.-d). Patent and exclusivity information. https://www.fda.gov/drugs/development-approval-process-drugs/drug-approval-package
U.S. Food and Drug Administration. (2018). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. https://www.fda.gov/regulatory-information/search-fda-guidance-documents
Haleon plc. (2023). Annual report and accounts 2022. https://www.haleon.com/investors/results-centre
GlaxoSmithKline plc. (2022). Annual report 2021. https://www.gsk.com/en-gb/investors/financial-results/annual-reports/

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	4
Patent Applications:	325
Drug Prices:	Drug price information for BECONASE AQ
DailyMed Link:	BECONASE AQ at DailyMed

BECONASE AQ Drug Patent Profile

Which patents cover Beconase Aq, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for BECONASE AQ

Recent Clinical Trials for BECONASE AQ

US Patents and Regulatory Information for BECONASE AQ

BECONASE AQ Market Dynamics, Patent Position, and Financial Trajectory